𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Biochemical basis for the selection of hormonal manipulation in the patient with breast carcinoma

✍ Scribed by James L. Wittliff; Edwin D. Savlov

Publisher
Elsevier Science
Year
1978
Tongue
English
Weight
569 KB
Volume
4
Category
Article
ISSN
0360-3016

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

The replication error phenotype is assoc
The replication error phenotype is associated with the development of distant metastases in hormonally treated patients with breast carcinoma
✍ Anees Chagpar; Anthony Magliocco; Annette Kerviche; Leonard Tan; Barbara Walley; πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 147 KB

## Abstract ## BACKGROUND The positive replication error (RER+) phenotype defines a distinct subgroup of tumors with specific clinical, pathologic, and molecular features that have been documented well in hereditary nonpolyposis colon carcinoma (HNPCC). More recently, this phenotype also has been

Selective modulation of postmenopausal w
Selective modulation of postmenopausal women : Cutting the Gordian knot of hormone replacement therapy with breast carcinoma
✍ Evanthia Diamanti-Kandarakis; Gerasimos P. Sykiotis; Athanasios G. Papavassiliou πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 101 KB

## Abstract ## BACKGROUND Hormone replacement therapy (HRT) has proven and presumable benefits for women desiring postmenopausal health preservation. Among HRT‐associated risks, the fear of breast carcinoma intimidates women and physicians contemplating hormonal treatment and limits long‐term comp

Esophageal metastases and dysphagia in p
Esophageal metastases and dysphagia in patients with carcinoma of the breast
✍ E. Douglas Holyoke; Takuma Nemoto; Thomas L. Dao πŸ“‚ Article πŸ“… 1969 πŸ› John Wiley and Sons 🌐 English βš– 624 KB

Ten patients with dysphagia due to metastatic carcinoma of the breast have been treated at Roswell Park Memorial Institute over the period from January 1960 through December 1968. This number represents less than 0.5:; of the total number of patients with metastatic breast disease seen during this p